Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of dabrafenib + trametinib in previously treated BRAF V600E-mutant radioactive iodine-refractory differentiated thyroid cancer
CTR20212658Phase 3Active
- Sponsor
- 不适用/ 北京诺华制药有限公司
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dabrafenib + trametinib, trametinib in well-differentiated thyroid cancer (WDTC), sponsored by 不适用/ 北京诺华制药有限公司. Started Dec 2021; status: active.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20212658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212658.